This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ARHGEF9 / Rho guanine nucleotide exchange factor 9 · IHC design guide
Design Immunohistochemistry for ARHGEF9
Plan ARHGEF9 paraffin IHC around cytoplasmic staining that is most abundant in CNS tissue (HPA tissue IHC). Compare Purkinje cells with an undetected cell population (HPA tissue IHC), and start the catalog antibody at 1:100–1:300 (datasheet).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ARHGEF9 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic staining in several tissues (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic staining; Purkinje cells and cortical neuropil (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific); target-specific effects are unclear. | |
| Caveat | Hippocampal glia are undetected despite CNS enrichment (HPA tissue IHC) | |
| Regulation | CNS-enriched staining (HPA tissue IHC) | |
| Isoform / epitope | 3 isoforms; splice-dependent epitope coverage is unknown (UniProt) |
Section 1
Recommended ARHGEF9 IHC & IF Protocols
The catalog antibody’s IHC-P protocol (datasheet) is accompanied by a published mouse-brain IHC protocol (PMC6066644).
| Sample | Paraffin-embedded human lung carcinoma tissue; fixative not specified (datasheet A06931-1) |
| Fixation | Image fixative and duration unreported (datasheet A06931-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-ARHGEF9, 1:100 - 1:300 (datasheet A06931-1) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ARHGEF9-positive staining in glandular cells of adrenal gland (HPA tissue IHC: Medium). HPA tissue profile: Cytoplasmic expression in several tissue, most abundant CNS. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 heat retrieval at 95–98 °C for 20 min (page retrieval); the published protocol also uses citrate pH 6.0 (PMC6066644).
Section 2
What Is the Expected ARHGEF9 Staining Pattern?
In paraffin-section IHC, expect predominantly cytoplasmic ARHGEF9 staining, especially in CNS structures, including cerebellar Purkinje cells and cerebral cortical neuropil (HPA: tissue IHC). A postsynaptic-density association is also annotated (UniProt O43307: subcellular location). ARHGEF9 has no transmembrane segment, so a continuous cell-surface rim is unexpected (UniProt O43307: topology). HPA rates its tissue IHC profile Approved, with external verification pending (HPA: tissue IHC reliability).
| Medium cytoplasmic staining in Purkinje cells, or staining in cortical neuropil. | These match the recorded CNS-positive structures (HPA: cerebellum and cerebral cortex, Medium). Score the named cell or structure; a cortical neuropil result does not establish that every cortical cell is positive (HPA: tissue IHC). |
| A dominant nuclear signal or a sharp, continuous plasma-membrane rim. | This conflicts with the reported cytoplasmic tissue pattern and cytoplasmic/postsynaptic annotation (HPA: tissue IHC; UniProt O43307: location). Check staining controls and morphology before attributing that compartment to ARHGEF9 (general IHC practice). |
| Prominent staining in hippocampal glial cells or lung alveolar cells. | Both named cell populations are recorded as Not detected (HPA: hippocampus and lung). Suspect nonspecific binding or endogenous chromogenic activity; the finding alone does not prove cross-reactivity (general IHC practice). |
| Haze across tissue and blank spaces, obscuring cell boundaries. | That distribution cannot be read as the cell-restricted pattern described by HPA (HPA: tissue IHC). Review the no-primary control, blocking, washes and detection background before assigning positive cells (general IHC practice). |
| No visible signal in cerebellar Purkinje cells or cortical neuropil. | These are recorded Medium-positive structures (HPA: cerebellum and cerebral cortex). Confirm that the structures are present, then check the antibody and detection run against a working positive control (general IHC practice). |
💡Expected ARHGEF9 appearanceCall a positive result when the named cells or structures show chiefly cytoplasmic, approximately Medium staining; a dominant nuclear or continuous membrane pattern is suspect (HPA: tissue IHC; UniProt O43307: topology).
| Cell-level reference pattern | HPA records Medium staining in Purkinje cells, cortical neuropil, adrenal glandular cells and hepatocytes, among others (HPA: tissue IHC). Its Not detected calls apply to specified cells, not necessarily every cell in those tissues (HPA: tissue IHC). |
| Subcellular interpretation | Cytoplasm and postsynaptic density are UniProt annotations; tissue IHC is described as cytoplasmic (UniProt O43307: location; HPA: tissue IHC). These support compartment scoring but do not require visible postsynaptic puncta in chromogenic sections. |
| Antibody evidence | HPA035419 is Approved for IHC, while the tissue profile is pending external verification (HPA: antibodies; HPA: tissue IHC reliability). An Approved call should not be presented as Enhanced validation (HPA: antibody-validation categories). |
| Isoforms and epitope | Three isoforms and SH3, DH and PH domains are annotated (UniProt O43307: isoforms and domains). The supplied record gives no antibody epitope, so isoform coverage and any domain-dependent staining difference cannot be assigned. |
| IF/ICC Q&A: where is signal expected? | HPA reports supported cytosolic localization in ICC-IF and lists A-431, U-251MG and NIH 3T3 images (HPA: subcellular). That observation answers localization only; this section's primary readout is paraffin-section IHC. |
| Situation | Likely cause | Next action |
|---|---|---|
| CNS positive control is blank. | The expected Purkinje-cell or cortical-neuropil signal is missing (HPA: cerebellum and cerebral cortex, Medium); the failed step is not identifiable from that observation alone. | Check that the named structure is on the section. Review antibody identity, dilution, antigen-retrieval conditions and detection reagents against the run controls (general IHC practice). |
| Only faint signal appears in caudate neurons. | Low staining is recorded for this cell population (HPA: caudate neuronal cells, Low), so faint signal there is less informative than a Medium-positive reference. | Compare with Purkinje cells or cortical neuropil on a matched staining run before changing conditions (HPA: cerebellum and cerebral cortex, Medium; general IHC practice). |
| Nuclei or cell borders dominate the stain. | That compartment differs from the cytoplasmic tissue profile; ARHGEF9 lacks a transmembrane segment (HPA: tissue IHC; UniProt O43307: topology). | Inspect the no-primary control and reduce nonspecific detection background as indicated by the control; reassess cell boundaries and counterstain (general IHC practice). |
| Alveolar cells stain strongly. | Alveolar cells are recorded as Not detected (HPA: lung). Nonspecific antibody binding or endogenous chromogenic activity is possible (general IHC practice). | Run a no-primary control and check any enzyme-blocking step appropriate to the detection system before interpreting the signal (general IHC practice). |
| The whole section has diffuse brown background. | Widespread deposition can obscure the recorded cell pattern (HPA: tissue IHC; general IHC practice). Its source requires controls rather than a target-specific assumption. | Check no-primary and tissue controls; review blocking, washes, antibody dilution and chromogen development for the assay (general IHC practice). |
| A named HPA-negative cell population appears positive. | HPA calls adipocytes in adipose tissue and hippocampal glial cells Not detected (HPA: tissue IHC). A discrepant stain needs validation; it does not by itself establish new expression. | Confirm cell identity and compare with a Medium-positive structure in the same run; use a no-primary control to assess detection background (HPA: tissue IHC; general IHC practice). |
Experiment evidence
IHC & IF images showing ARHGEF9 staining
A06931-1 · IHCImmunohistochemistry analysis of paraffin-embedded human lung carcinoma tissue, using ARHGEF9 Antibody. The picture on the right is blocked
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000131089-ARHGEF9/tissue/cerebral+cortex#imid_9022004
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000131089-ARHGEF9/tissue/colon#imid_9011362
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000131089-ARHGEF9/tissue/liver#imid_9011363
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000131089-ARHGEF9/tissue/kidney#imid_9011364
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA055291; green = ARHGEF9, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA055291; green = ARHGEF9, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ARHGEF9 IHC & IF
🧪Run cerebellum first and look for staining in Purkinje cells (HPA: Medium in cerebellar Purkinje cells); use adipose tissue as the negative tissue and expect adipocytes to lack staining (HPA: Not detected in adipocytes). On the cerebellum slide, cells that appear unstained should show only counterstain, but the supplied HPA rows do not establish a specific internal cell population as ARHGEF9-negative (HPA: cerebellum row).
Positive control tissue: Adrenal gland (Glandular cells, HPA Medium)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ARHGEF9 in A-431, U-251MG, NIH 3T3, with annotated localisation: Cytosol (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and an isotype control matched to the primary antibody’s host species and clonality; use knockout tissue or a validated peptide block as a biological specificity control (standard IHC practice). Check endogenous peroxidase activity in the chromogenic assay, and check neuronal autofluorescence if examining cerebellum by IF (standard IHC/IF practice).
⚠️Feasibility: A target-specific fixation window and the effect of fixation are unreported; the selected A06931-1 paraffin-section caption also leaves the fixative unreported (selected-SKU tissue-IHC caption). Antigen-retrieval dependency is unreported, so compare retrieval conditions with a no-retrieval section when optimizing IHC (standard IHC practice). The supplied evidence does not establish whether frozen sections or IF are easier; neuronal autofluorescence is a potential cerebellar IF artefact to assess with an unstained section (standard IF practice).
HPA tissue IHC evidence for ARHGEF9
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Medium | Protein (IHC) | HPA → |
| Cerebellum | Purkinje cells | Medium | Protein (IHC) | HPA → |
| Cerebral cortex | Neuropil | Medium | Protein (IHC) | HPA → |
| Colon | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Esophagus | Squamous epithelial cells | Not detected | Protein (IHC) | HPA → |
| Fallopian tube | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced ARHGEF9 IHC Tips
Troubleshoot ARHGEF9 staining in paraffin sections by checking retrieval, compartment, cell identity, and controls before comparing signal intensity.
How should I retrieve ARHGEF9 in paraffin sections when cytoplasmic staining is weak?
Use citrate buffer at pH 6.0 for heat-induced retrieval at 95–98 °C for 20 minutes (page retrieval setting). Cool sections consistently before staining, and compare a retrieved section with an otherwise matched section to distinguish insufficient retrieval from staining that persists without retrieval (standard IHC practice). If signal remains weak, adjust retrieval duration in small steps while watching for tissue damage; keep antibody incubation and chromogen development constant during that comparison (standard IHC practice). Evaluate cytoplasmic staining in a relevant cell population, such as cerebellar Purkinje cells, rather than treating stronger background as recovered antigen (HPA: Medium in Purkinje cells; HPA: cytoplasmic tissue expression).
Could fixation explain variable ARHGEF9 staining between paraffin blocks?
ARHGEF9-specific sensitivity to fixation is unknown from the supplied evidence; the selected antibody image describes paraffin-embedded lung carcinoma but gives no fixative (selected SKU A06931-1 caption). Record each block’s fixative and fixation interval when available, then compare sections processed with the same retrieval, antibody incubation, and detection conditions (standard IHC practice). Use a control section with a known staining pattern in every run to separate block variation from a failed staining run (standard IHC practice; HPA: Medium in cerebellar Purkinje cells). Do not attribute a weak block to a particular fixation mechanism without a controlled comparison, especially when its preanalytic history is incomplete (standard IHC practice).
Where should convincing ARHGEF9 staining appear in tissue sections?
Look first for cytoplasmic signal, with possible enrichment in neuronal processes or synaptic regions, because ARHGEF9 is assigned to the cytoplasm and postsynaptic density (UniProt O43307: subcellular location; HPA: cytoplasmic tissue expression). The supported cell-level location is cytosol, so a crisp nuclear-only pattern needs independent validation before it is scored as ARHGEF9 (HPA: cytosol supported). Compare neuropil and Purkinje-cell staining with adjacent cellular compartments at the same chromogen development time (HPA: Medium in cerebral cortex neuropil and cerebellar Purkinje cells; standard IHC practice). A membrane rim alone does not follow from the protein record, which lists no transmembrane segment (UniProt O43307: topology).
Could isoform choice or epitope masking alter my ARHGEF9 IHC result?
The record lists 3 ARHGEF9 isoforms, so first establish which sequence region the antibody recognizes before interpreting an absent tissue signal (UniProt O43307: isoforms). Map any disclosed epitope against the SH3 domain at residues 8–67, DH domain at 103–287, and PH domain at 318–425 (UniProt O43307: domains). If the epitope is undisclosed, do not claim that a negative section excludes every isoform; compare a second antibody with a disclosed, distinct epitope when available (standard IHC validation practice). Phosphoserine 502 is recorded, but its effect on this antibody’s binding is not established by the supplied evidence (UniProt O43307: modified residues).
How can I check ARHGEF9 localisation by IF alongside this chromogenic IHC assay?
Use IF as a separate localisation check and multiplex ARHGEF9 with an independently validated marker for the expected cell population, such as Purkinje cells in cerebellum (HPA: Medium in Purkinje cells; standard IF practice). Choose fluorophores after inspecting unstained tissue for autofluorescence, and reserve a spectrally separated channel for the weaker signal (standard IF practice). ARHGEF9 has no transmembrane segment and is reported in cytosol and postsynaptic density, so use controlled permeabilisation when testing intracellular epitopes (UniProt O43307: topology and location; HPA: cytosol supported). Include single-stain and secondary-only controls to assess bleed-through and nonspecific fluorescence before comparing IF patterns with the chromogenic section (standard IF practice).
What should I check when ARHGEF9 chromogen appears throughout the section?
Run a no-primary control and inspect whether diffuse color persists, especially where endogenous peroxidase or nonspecific detection could contribute (standard chromogenic IHC practice). Include a peroxidase block before enzyme-based detection and adjust blocking, washes, and chromogen development while keeping the comparison sections otherwise matched (standard IHC practice). The selected SKU image includes peptide blocking, which supports checking antibody-dependent staining under that pictured condition but does not establish specificity in every tissue (selected SKU A06931-1 caption). Compare the distribution against reported cytoplasmic expression and avoid calling uniform staining of every compartment a positive ARHGEF9 pattern (HPA: cytoplasmic tissue expression; standard IHC interpretation).
How should I score ARHGEF9 IHC across regions with different cell composition? ⚠ ANSWER MARKED FOR VERIFICATION
Define the region and eligible cell type before scoring, then report either percent positive cells with intensity or an H-score using the same thresholds across sections (standard IHC quantification practice). For neuropil, quantify chromogen-positive area or optical density per unit tissue area instead of forcing a cell count onto processes (HPA: Medium in cerebral cortex neuropil; standard image-analysis practice). Normalize cellular scores to the number of evaluable cells and area measurements to non-necrotic tissue area, recording section area and staining batch (standard IHC practice). Keep neuronal and glandular compartments separate because the reference profile includes both CNS enrichment and medium staining in several glandular cell populations (HPA: tissue profile).
How can I distinguish genuine ARHGEF9 staining from tissue artefact?
Favor a reproducible cytoplasmic or neuropil pattern in the expected cells, supported by a control section stained in the same run (UniProt O43307: cytoplasm and postsynaptic density; HPA: Medium in cerebral cortex neuropil; standard IHC practice). Treat isolated nuclear staining or a sharp membrane-only outline as questionable until another assay supports it (HPA: cytosol supported; UniProt O43307: no transmembrane segment). Examine section edges and necrotic areas separately, since uneven processing can produce staining unrelated to the scored cell population (standard IHC practice). Check no-primary and peroxidase-block controls when color persists broadly, and interpret the selected peptide-blocking image only as evidence for its pictured paraffin-embedded lung carcinoma condition (standard IHC practice; selected SKU A06931-1 caption).
Boster reagents
Best ARHGEF9 / Rho guanine nucleotide exchange factor 9 IHC Antibodies
The catalog antibody covers human, mouse and rat IHC and IF applications (catalog: A06931-1); its IHC figure shows paraffin-embedded human lung carcinoma tissue (IHC image caption).
Real IHC data
Anti-ARHGEF9/Collybistin Antibody
Cat # A06931-1
A06931-1 will render with an IHC figure of paraffin-embedded human lung carcinoma tissue and a peptide-blocked comparison (IHC image caption). Its listed applications include IHC, IF and ICC, with human, mouse and rat reactivity; no IF figure is supplied (catalog: A06931-1).
Which to pick: Choose A06931-1 for paraffin-section IHC because its own figure documents that processing in human lung carcinoma tissue; the fixative is unreported (IHC image caption). The same polyclonal antibody is listed for IF and ICC, with human, mouse and rat reactivity, though the payload supplies no IF figure or cross-species tissue image (catalog: A06931-1).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry O43307 (ARHG9_HUMAN, Rho guanine nucleotide exchange factor 9).
- Human Protein Atlas. ARHGEF9 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. ARHGEF9 subcellular location (ICC-IF): Localized to the cytosol..
- Human Protein Atlas. ARHGEF9 antibody validation summary (2 antibodies).
- Biochemical and Morphological Characterization of a Guanine Nucleotide Exchange Factor ARHGEF9 in Mouse Tissues. Acta histochemica et cytochemica 2018 — PMC6066644.
- PubMed PMID:9455477 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:15772651 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ARHGEF9 (Rho guanine nucleotide exchange factor 9). Expected localisation Cytoplasmic staining in several tissues (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A06931-1 at 1:100 - 1:300 (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human lung carcinoma tissue; fixative not specified (datasheet A06931-1); 2. Fixation: Image fixative and duration unreported (datasheet A06931-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-ARHGEF9, 1:100 - 1:300 (datasheet A06931-1); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific); target-specific effects are unclear.; Caveat: Hippocampal glia are undetected despite CNS enrichment (HPA tissue IHC); Isoform / epitope: 3 isoforms; splice-dependent epitope coverage is unknown (UniProt); Regulation: CNS-enriched staining (HPA tissue IHC). Evidence: UniProt O43307, HPA tissue IHC · Approved, HPA ICC-IF · cytosol., Datasheet A06931-1, PMC6066644. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ARHGEF9/immunohistochemistry-ihc-guide.